Compass Therapeutics Stock Today
| CMPX Stock | USD 2.24 0.02 0.88% |
PerformanceOK
| Odds Of DistressLow
|
Compass Therapeutics is trading at 2.24 as of the 21st of March 2025; that is 0.88% down since the beginning of the trading day. The stock's open price was 2.26. Compass Therapeutics has about a 22 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of March 20232023 | Category Healthcare | Classification Health Care |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Compass Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 138.28 M outstanding shares of which 3.53 M shares are currently shorted by private and institutional investors with about 3.05 trading days to cover. More on Compass Therapeutics
Moving together with Compass Stock
Moving against Compass Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Compass Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| General President | Jonathan JD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCompass Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Compass Therapeutics' financial leverage. It provides some insight into what part of Compass Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Compass Therapeutics (CMPX) is traded on NASDAQ Exchange in USA. It is located in 80 Guest Street, Boston, MA, United States, 02135 and employs 35 people. Compass Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 319.43 M. Compass Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 138.28 M outstanding shares of which 3.53 M shares are currently shorted by private and institutional investors with about 3.05 trading days to cover.
Compass Therapeutics currently holds about 132.02 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31.
Check Compass Therapeutics Probability Of Bankruptcy
Ownership AllocationCompass Therapeutics holds a total of 138.28 Million outstanding shares. The majority of Compass Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Compass Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Compass Therapeutics. Please pay attention to any change in the institutional holdings of Compass Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Compass Ownership Details
Compass Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blue Owl Capital Holdings Lp | 2024-12-31 | 3 M | |
| Geode Capital Management, Llc | 2024-12-31 | 2.3 M | |
| State Street Corp | 2024-12-31 | 1.9 M | |
| Baker Bros Advisors Lp | 2024-12-31 | 1.6 M | |
| Northern Trust Corp | 2024-12-31 | 801.2 K | |
| Monashee Investment Management Llc | 2024-12-31 | 448.2 K | |
| Sg Americas Securities, Llc | 2024-12-31 | 395 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 390.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 378.6 K | |
| Orbimed Advisors, Llc | 2024-12-31 | 22.4 M | |
| Blackstone Inc | 2024-12-31 | 10 M |
Compass Therapeutics Historical Income Statement
Compass Stock Against Markets
Compass Therapeutics Corporate Management
| Susan Kalled | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Barry JD | Chief Officer | Profile | |
| Neil CPA | Vice Finance | Profile | |
| Peter Moesta | Interim CMC | Profile | |
| Anna Gifford | Communications Manager | Profile |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.